27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Galectin Therapeutics Inc (NASDAQ:GALT) has announced top-line clinical data from the extension cohort of Phase 1b trial of Belapectin in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) in patients with metastatic melanoma and head & neck cancer.
- The extension study enrolled heavily-pretreated nine melanoma patients and five head & neck squamous cell carcinoma cancer patients.
- Melanoma patient results included one partial response, four stable diseases, and four progressive diseases, providing a disease control rate of 56% (five out of nine patients).
- In head and neck cancer patients, two stable diseases and three progressive diseases, providing a disease control rate of 40% (two out of five patients), were reported.
- The combination of Belapectin and pembrolizumab was well tolerated and appeared safe.
- No toxicities deemed related, probably related, or possibly related to Belapectin were reported.
- Belapectin (GR-MD-02) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis, and has a significant role in cancer.
- Price Action: GALT shares are up 44.6% at $3.99 during the premarket session on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!